Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Maja Rothenberg-Thurley, PhD, Stephanie Schneider, Dr. rer. nat., Tobias Herold, MD, Nikola P Konstandin, Annika Dufour, PhD, Kathrin Bräundl, Bianka Ksienzyk, Evelyn Zellmeier, Philipp A Greif, MD, Michael Fiegl, MD, Marion S. Subklewe, MD, Stefan K Bohlander, MD, Wolfgang Hiddemann, MD, Jan Braess, MD, Karsten Spiekermann, MD, Klaus H. Metzeler, MD

Blood (2014) 124 (21): 697.

https://doi.org/10.1182/blood.V124.21.697.697

Published: 2014

Journal Articles

Genetic Characterization of Patients with Monoallelic and Biallelic CEBPA Mutations Using a Targeted Sequencing Approach Reveals Differences in the Spectrum of Cooperating Mutations

Nikola P Konstandin, Klaus H. Metzeler, MD, Annika Dufour, PhD, Philipp A Greif, MD, Tobias Herold, MD, Bianka Ksienzyk, Stephanie Schneider, Dr. rer. nat., Wolfgang E Berdel, MD, Thomas Büchner, MD, Bernhard J. Woermann, MD, Cristina Sauerland, MSc, Jan Braess, MD, Wolfgang Hiddemann, MD, Stefan K Bohlander, MD, Karsten Spiekermann, MD

Blood (2014) 124 (21): 2385.

https://doi.org/10.1182/blood.V124.21.2385.2385

Published: 2014

Journal Articles

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

Max Hubmann, MD, Christina Zeber, Markus Pfirrmann, PhD, Thomas Koehnke, MD, Nicole Engel, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Evelyn Zellmeier, Roland Reibke, MD, Hans-Jochem Kolb, PhD, Marion Subklewe, MD, Michael Fiegl, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 1178.

https://doi.org/10.1182/blood.V124.21.1178.1178

Published: 2014

Journal Articles

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Blood (2013) 122 (21): 1303.

https://doi.org/10.1182/blood.V122.21.1303.1303

Published: 2013

Journal Articles

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

Blood (2013) 122 (21): 608.

https://doi.org/10.1182/blood.V122.21.608.608

Published: 2013

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Whole Exome Sequencing of CLL Before Second-Line Treatment with Fludarabine and Cyclophosphamide with or without Rituximab (REACH trial).

Nikola P Konstandin, Annika Dufour, PhD, Philipp A Greif, MD, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Stephanie Schneider, PhD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, PhD, Kerstin Trunzer, PhD, Martin Weisser, MD, Stefan K Bohlander, MD

Blood (2012) 120 (21): 2514.

https://doi.org/10.1182/blood.V120.21.2514.2514

Published: 2012

Journal Articles

Analysis of Cooperating Genetic Events in MLLT3-MLL Rearranged Acute Myeloid Leukemia (AML) by Targeted Next-Generation Sequencing of 16 Leukemia-Related Genes Reveals Frequent Mutations Affecting Growth Factor Signalling Pathways and Provides Evidence for Clonal Heterogeneity

Klaus H. Metzeler, MD, Nadine Sandhöfer, Tanja Hinrichsen, Evelyn Zellmeier, Bianka Ksienzyk, Annika Dufour, PhD, Stephanie Schneider, PhD, Purvi M. Kakadia, PhD, Philipp A Greif, MD, Marion S. Subklewe, MD, Stefan K Bohlander, MD, Hanns-Georg Klein, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2012) 120 (21): 1379.

https://doi.org/10.1182/blood.V120.21.1379.1379

Published: 2012

Journal Articles

Quantitative Monitoring of NPM1 Mutation A Minimal Residual Disease Identifies Patients At High Risk for Relapse within the ELN Favorable Risk Group

Max Hubmann, MD, Marion Subklewe, MD, Thomas Köhnke, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Evelyn Zellmeier, Michael Fiegl, MD, Wolfgang Hiddemann, MD, PhD, Karsten Spiekermann, PhD

Blood (2012) 120 (21): 1404.

https://doi.org/10.1182/blood.V120.21.1404.1404

Published: 2012

Journal Articles

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

Sabrina Opatz, Harald Polzer, Tobias Herold, MD, Nikola P Konstandin, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Karl Peter Hopfner, PhD, Purvi M. Kakadia, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Jan Braess, MD, Michael Heuser, MD, Wolfgang Hiddemann, MD, PhD, Karsten Spiekermann, MD, Stefan K Bohlander, MD, Philipp A Greif, MD

Blood (2012) 120 (21): 404.

https://doi.org/10.1182/blood.V120.21.404.404

Published: 2012

Journal Articles

High Frequency of GATA2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia with Biallelic CEBPA Mutations Identified by Exome Sequencing

Blood (2011) 118 (21): 72.

https://doi.org/10.1182/blood.V118.21.72.72

Published: 2011

Journal Articles

High Expression of the Endoplasmic Reticulum Protein MZB1 predicts Inferior Prognosis in Chronic Lymphocytic Leukemia, Follicular Lymphoma and Diffuse Large B-Cell Lymphoma and Is Associated with a Unique Gene Expression Profile,

Tobias Herold, MD, Medhanie A Mulaw, PhD, Vindi Jurinovic, Till M Seiler, MD, Klaus H. Metzeler, MD, Annika Dufour, PhD, Stephanie Schneider, PhD, Purvi Kakadia, PhD, Karsten Spiekermann, MD, Ulrich Mansmann, Wolfgang Hiddemann, MD, Christian Buske, Martin H. Dreyling, PhD, Stefan K Bohlander, MD

Blood (2011) 118 (21): 3657.

https://doi.org/10.1182/blood.V118.21.3657.3657

Published: 2011

Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Blood (2011) 118 (21): 3521.

https://doi.org/10.1182/blood.V118.21.3521.3521

Published: 2011

Journal Articles

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

Friederike Schneider, Eva Hoster, PhD, Marietta Rottenkolber, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Stefan K. Bohlander, MD, Michael Unterhalt, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Jan Braess, MD, Achim Heinecke, PhD, Wolfgang E. Berdel, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3482.

https://doi.org/10.1182/blood.V110.11.3482.3482

Published: 2007

Journal Articles

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Stephanie Schneider, PhD, Friederike Schneider, Annika Dufour, PhD, Gudrun Mellert, Evelyn Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard J. Wormann, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3486.

https://doi.org/10.1182/blood.V110.11.3486.3486

Published: 2007

Journal Articles

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Karsten Spiekermann, MD, Annika Dufour, PhD, Gudrun Mellert, Evelin Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, MD, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard Josef Wormann, MD, Thomas Buchner, MD, Wolfgang Hiddemann, MD, Acute Myeloid Leukemia Cooperative Group (AMLCG)

Blood (2006) 108 (11): 805.

https://doi.org/10.1182/blood.V108.11.805.805

Published: 2006

NARROW

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Genetic Characterization of Patients with Monoallelic and Biallelic CEBPA Mutations Using a Targeted Sequencing Approach Reveals Differences in the Spectrum of Cooperating Mutations

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Whole Exome Sequencing of CLL Before Second-Line Treatment with Fludarabine and Cyclophosphamide with or without Rituximab (REACH trial).

Analysis of Cooperating Genetic Events in MLLT3-MLL Rearranged Acute Myeloid Leukemia (AML) by Targeted Next-Generation Sequencing of 16 Leukemia-Related Genes Reveals Frequent Mutations Affecting Growth Factor Signalling Pathways and Provides Evidence for Clonal Heterogeneity

Quantitative Monitoring of NPM1 Mutation A Minimal Residual Disease Identifies Patients At High Risk for Relapse within the ELN Favorable Risk Group

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

High Frequency of GATA2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia with Biallelic CEBPA Mutations Identified by Exome Sequencing

High Expression of the Endoplasmic Reticulum Protein MZB1 predicts Inferior Prognosis in Chronic Lymphocytic Leukemia, Follicular Lymphoma and Diffuse Large B-Cell Lymphoma and Is Associated with a Unique Gene Expression Profile,

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only